Latest News

November 15, 2010
UCSF researchers have for the first time shown that an external optical pacemaker can be used in a vertebrate to control its heart rate.
November 09, 2010
UCSF Nobel laureate Stanley Prusiner, MD, and colleagues have called for Congress to more than quadruple annual federal funding for Alzheimer’s research, saying that with a dedicated effort, there is a chance for a breakthrough against the disease by 2020.
November 03, 2010
Researchers at the Ernest Gallo Clinic and Research Center at UCSF, and Pfizer Inc., have determined that two new compounds may be effective in treating both alcohol and nicotine dependence at the same time.
November 01, 2010
Rapamycin, an FDA-approved drug prescribed to prevent the rejection of transplanted organs, has been shown for the first time to decrease excessive alcohol consumption, binge drinking, and alcohol-seeking behavior in rodents.
October 22, 2010
UCSF scientists have received two grants from the California Institute for Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure.
October 15, 2010
UCSF Nobel laureate Stanley B. Prusiner, professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation’s highest honor for science and technology.
October 04, 2010
Synuclein is a protein that can cause Parkinson’s disease, although it is not clear how. UCSF researcher Robert Edwards, MD, now has discovered that synuclein can affect signal transmission between nerve cells long before disease symptoms arise.
September 21, 2010
An inexpensive, hundred-year-old therapy for pain – aspirin – is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center.
August 30, 2010
UCSF is co-sponsoring a symposium on September 27 and 28 to provide scientists and physicians with the “nuts and bolts” of translating stem cell science into cell-based products for clinical trials.
August 10, 2010
In neurodegenerative diseases, clumps of insoluble proteins appear in patients’ brains. These aggregates contain proteins that are unique to each disease, such as amyloid beta in Alzheimer’s disease, but they are intertwined with small amounts of many other insoluble proteins that are normally present in a soluble form in healthy young individuals.

Pages